Cite

    Francesc Formiga et al.. “Health and economic impact of the correct diagnosis of transthyretin cardiac amyloidosis in Spain.” Expert review of pharmacoeconomics & outcomes research, vol. 21, 2021, pp. 1127–1133. http://access.bl.uk/ark:/81055/vdc_100142225342.0x000022